The Ubiquitin System: From Basic Science to Drug Discovery

Organized by Ingrid E. Wertz of Genentech, Inc. and David Komander of MRC Laboratory of Molecular Biology, the four-day conference will:
• Focus on the ever-increasing range of cellular contexts in which ubiquitination plays a part and include updates on clinically-oriented studies relating to neurodegeneration, mitochondrial dysfunction and inflammation/infection;
• Incorporate two technology-focused workshops led by established international experts that focus on technological advances and the development of model systems for interrogating the ubiquitin system;
• Provide a balance of exciting science and room for discussion to foster collaborations between clinicians, translational researchers and basic scientists with interests ranging from the biophysics to the cellular biology of the ubiquitin system.

+ show speakers and program
Raymond J. Deshaies, California Institute of Technology, USA
Beyond the Proteasome: New Drug Targets in the Ubiquitin System

David Komander, MRC Laboratory of Molecular Biology, UK
Lys-6-Linked Ubiquitination

Michael Rape, University of California, Berkeley, USA
Lys-11-Linked Ubiquitination

Ingrid E. Wertz, Genentech, Inc., USA
Ubiquitin Editing

J. Wade Harper, Harvard Medical School, USA
Proteomic Approaches to Understanding the Ubiquitin Proteasome System

Brenda A. Schulman, St. Jude Children's Research Hospital, USA
Structural and Mechanistic Studies of Cullin-RING Ligases

Guy S. Salvesen, Sanford-Burnham Medical Research Institute, USA
Why is Addition and Removal of SUMO so Dynamic?

Christopher D. Lima, Memorial Sloan-Kettering Cancer Center, USA
Structural Basis for SUMO and Ubiquitin-Dependent Signal Transduction Pathways

Marcus Groettrup, University of Constance, Germany
FAT10 Regulation of the Ubiquitin Proteasome System

Heran Darwin, New York University School of Medicine, USA
The Mycobacterium Tuberculosis Pupylation Pathway

Matthias Peter, ETH Zürich, Switzerland
Nedd8 Regulation of the Ubiquitin Proteasome System

Ivan Dikic, Goethe University Medical School, Germany
Regulation of Autophagy by the Ubiquitin Proteasome System

Henning Walczak, Imperial College London, UK
Regulation of NF-kappaB by Ubiquitin Chains

Vishva M. Dixit, Genentech, Inc., USA
Ubiquitin-Mediated Modulation of Epigenetics

Ronald T. Hay, University of Dundee, UK
SUMO-Targeted Ubiquitination

Rachel Klevit, University of Washington, USA
Engineering E3 Ligases to Modulate Function

Wenyi Wei, Beth Israel Deaconess Medical Center, USA
Acetylation-Dependent Regulation of Skp2 Oncogenic Functions

Simona Polo, FIRC Institute of Molecular Oncology, Italy
Ubiquitin Ligases in Endocytosis

Hidde L. Ploegh, Whitehead Institute for Biomedical Research, USA
Bacterial Subversion of the Ubiquitin Proteasome System

Titia K. Sixma, Netherlands Cancer Institute, Netherlands
Insights into USP Deubiquitinases

Cynthia Wolberger, Johns Hopkins University School of Medicine, USA
Deubiquitinase Enzymes in Cancer

James Brownell, Millennium Pharmaceuticals, Inc., USA
Mechanism-Based E1 Inhibitors and New Insights into Ubiquitin-like Protein Conjugation

Gwen Nichols, Hoffmann-LaRoche, USA
Drugging E3 Ligase/Substrate Interactions: MDM2 Antagonist Clinical Development

Stephen P. Jackson, University of Cambridge, UK
Deubiquitinase Enzymes as Drug Targets

Christopher Kirk, Onyx Pharmaceuticals, USA
The Therapeutic Efficacy of Proteasome Inhibition

Iannis Aifantis, HHMI/New York University School of Medicine, USA
Regulation of Leukemogenesis by the Ubiquitin System

Alain Israël, Institut Pasteur, France
Ubiquitination in NF-kB Signaling

Daniel J. Finley, Harvard University, USA
Drugging DUBs in Disease

7 Jan - 12 Jan 2014
Big Sky
United States of America
meeting website